Logo

Eli Lilly and Innovent Report Results of Sintilimab + CT in P-III ORIENT-11 Study as 1L Treatment of NSCLC

Share this
Eli Lilly and Innovent Report Results of Sintilimab + CT in P-III ORIENT-11 Study as 1L Treatment of NSCLC

Eli Lilly and Innovent Report Results of Sintilimab + CT in P-III ORIENT-11 Study as 1L Treatment of NSCLC

Shots:

  • The P-III ORIENT-11 study evaluates the efficacy & safety of sintilimab (200mg) + pemetrexed and platinum CT vs PBO + CT in 397 patients in a ratio (2:1) as 1L treatment for advanced or metastatic nonsq. NSCLC without sensitizing EGFR mutations or ALK rearrangements
  • The results demonstrated an OS benefit with a median follow-up of 22.9mos.- m-OS (not reached vs 16.8mos.). Additionally- biomarker results provide insights for patients with high MHC class-II expression
  • Sintilimab is a PD-1 inhibitor- jointly developed by Eli Lilly & Innovent. Additionally- the regulatory submission is currently under review in China for sintilimab as 2L treatment of sq. NSCLC

| Ref: PR Newswire | Image: Innovent

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions